Radiopharm Theranostics (Radiopharm Theranostics) Other Long-Term Liabilities : $17.47 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics Other Long-Term Liabilities?

Radiopharm Theranostics's other long-term liabilities for the quarter that ended in Dec. 2023 was $17.47 Mil.

Radiopharm Theranostics's quarterly other long-term liabilities increased from Dec. 2022 ($5.44 Mil) to Jun. 2023 ($10.83 Mil) and increased from Jun. 2023 ($10.83 Mil) to Dec. 2023 ($17.47 Mil).

Radiopharm Theranostics's annual other long-term liabilities increased from . 20 ($0.00 Mil) to Jun. 2022 ($8.81 Mil) and increased from Jun. 2022 ($8.81 Mil) to Jun. 2023 ($10.83 Mil).

Radiopharm Theranostics Other Long-Term Liabilities Historical Data

The historical data trend for Radiopharm Theranostics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Other Long-Term Liabilities Chart

Radiopharm Theranostics Annual Data

Trend

Jun22

Jun23

Other Long-Term Liabilities

Radiopharm Theranostics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Other Long-Term Liabilities	-	-	-	-	-

Radiopharm Theranostics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Radiopharm Theranostics Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

RAD:Australia

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.radiopharmtheranostics.com

Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (Radiopharm Theranostics) Headlines

From GuruFocus

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire • 10-19-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-30-2022

RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB

By PRNewswire PRNewswire • 08-04-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 07-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-20-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-10-2022